Immune-related pneumonitis with nivolumab and ipilimumab during the COVID-19 pandemic

The city of São Paulo is the epicenter of the COVID-19 pandemic in South America. Until May 24th, 2020, a total 49,306 confirmed cases and 3,550 deaths were attributed to the new coronavirus (Sars-Cov-2) in the city.(1) As such, patients with acute respiratory symptoms with hospitalization criteria are usually admitted under the presumed diagnosis of COVID-19, until at least one negative reverse transcriptase polymerase chain reaction (RT-PCR) test. However, patients undergoing immune checkpoint inhibitors are at risk for immune-related pneumonitis.

Lascia un commento